Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
Nobuaki MatsubaraJohann S de BonoDavid OlmosGiuseppe ProcopioSatoru KawakamiYuksel UrunRobbert van AlphenAude FlechonMichael A CarducciYoung Deuk ChoiSebastien J HotteErnesto KorbenfeldGero KramerArchana M AgarwalKim N ChiSimon DeardenChristopher GrestyJinyu KangChristian PoehleinElizabeth A HarringtonMaha H A HussainPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
When tumor tissue testing is not feasible or has failed, ctDNA testing may be a suitable alternative to identify patients with mCRPC carrying BRCA/ATM alterations who may benefit from olaparib treatment.